Anticipating changes in the HER2 status of breast tumours with disease progression—towards better treatment decisions in the new era of HER2-low breast cancers

BACKGROUND: HER2 expression is often negative or low in primary breast cancers (BCs) but its changes with disease progression remain poorly known. We aimed to estimate them between primary and recurrent tumours, and identify predictive factors. METHODS: We compared the HER2 status, and clinical and...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergeron, Anthony, Bertaut, Aurélie, Beltjens, Françoise, Charon-Barra, Céline, Amet, Alix, Jankowski, Clémentine, Desmoulins, Isabelle, Ladoire, Sylvain, Arnould, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307899/
https://www.ncbi.nlm.nih.gov/pubmed/37120672
http://dx.doi.org/10.1038/s41416-023-02287-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307899/
https://www.ncbi.nlm.nih.gov/pubmed/37120672
http://dx.doi.org/10.1038/s41416-023-02287-x

Ejemplares similares